Hypoxia-induced shift in the phenotype of proteasome from 26S toward immunoproteasome triggers loss of immunoprivilege of mesenchymal stem cells

Allogeneic mesenchymal stem cells (MSCs) are immunoprivileged and are being investigated in phase I and phase II clinical trials to treat different degenerative and autoimmune diseases. In spite of encouraging outcome of initial trials, the long-term poor survival of transplanted cells in the host t...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-El-Rub, Ejlal, Sareen, Niketa, Yan, Weiang, Alagarsamy, Keshav Narayan, Rafieerad, Alireza, Srivastava, Abhay, Desiderio, Vincenzo, Dhingra, Sanjiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272449/
https://www.ncbi.nlm.nih.gov/pubmed/32499535
http://dx.doi.org/10.1038/s41419-020-2634-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272449/
https://www.ncbi.nlm.nih.gov/pubmed/32499535
http://dx.doi.org/10.1038/s41419-020-2634-6

Ejemplares similares